ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.21) by 47.62 percent. This is a 56 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $19.248 million which missed the analyst consensus estimate of $19.376 million by 0.66 percent. This is a 2.17 percent increase over sales of $18.839 million the same period last year.